Technical Analysis for STTK - Shattuck Labs, Inc.

Grade Last Price % Change Price Change
F 1.01 -9.01% -0.10
STTK closed down 2.63 percent on Wednesday, November 20, 2024, on 23 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness -9.01%
Outside Day Range Expansion -9.01%
Lower Bollinger Band Touch Weakness -9.01%
Oversold Stochastic Weakness -9.01%
Lower Bollinger Band Walk Weakness -11.40%
Stochastic Reached Oversold Weakness -11.40%
Lower Bollinger Band Touch Weakness -11.40%
Oversold Stochastic Weakness -11.40%
20 DMA Resistance Bearish -8.60%
New 52 Week Closing Low Bearish -8.60%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 1 hour ago
Down 5% about 3 hours ago
Down 3% about 3 hours ago
Fell Below Lower Bollinger Band about 3 hours ago
New 52 Week Low about 3 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian cancer. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was founded in 2016 and is headquartered in Austin, Texas.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Life Sciences Solid Tumors Autoimmune Disease Treatment Of Cancer Lymphoma Clinical Research Clinical Trial Ovarian Cancer Advanced Solid Tumors Clinical Pharmacology Treatment Of Ovarian Cancer

Is STTK a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 11.76
52 Week Low 1.07
Average Volume 726,877
200-Day Moving Average 5.64
50-Day Moving Average 1.93
20-Day Moving Average 1.24
10-Day Moving Average 1.20
Average True Range 0.15
RSI (14) 35.06
ADX 34.54
+DI 19.26
-DI 25.25
Chandelier Exit (Long, 3 ATRs) 1.11
Chandelier Exit (Short, 3 ATRs) 1.54
Upper Bollinger Bands 1.39
Lower Bollinger Band 1.09
Percent B (%b) 0.08
BandWidth 24.32
MACD Line -0.18
MACD Signal Line -0.22
MACD Histogram 0.0422
Fundamentals Value
Market Cap 52.32 Million
Num Shares 47.1 Million
EPS -2.24
Price-to-Earnings (P/E) Ratio -0.50
Price-to-Sales 323.03
Price-to-Book 3.76
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.27
Resistance 3 (R3) 1.28 1.23 1.24
Resistance 2 (R2) 1.23 1.19 1.23 1.23
Resistance 1 (R1) 1.17 1.17 1.15 1.16 1.22
Pivot Point 1.13 1.13 1.12 1.12 1.13
Support 1 (S1) 1.07 1.09 1.05 1.06 1.00
Support 2 (S2) 1.02 1.06 1.02 0.99
Support 3 (S3) 0.96 1.02 0.98
Support 4 (S4) 0.95